ArticleRheumatology (Oxford, England)2026
Predictors and long-term impact of sustained complete renal response in lupus nephritis patients over a median 10-year follow-up.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kidney Biopsy and Prognosis in Lupus Nephritis: Histological Predictors of Renal Outcome-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesComplete renal response (CRR) is a primary goal in lupus nephritis (LN) management. We examined the prevalence and predictors of sustained CRR (sCRR) and long-term outcomes.
methodsWe included 142 inception cohort patients with biopsy-proven LN from two academic centres. We assessed the prevalence of sCRR achievement for ≥12 months and the impact of sCRR duration on renal flares, severe kidney function decline (≥30% eGFR decline compared with baseline), a composite end-stage kidney disease (ESKD) or death outcome, and disease damage. We analysed data over a median 121-month follow-up, using linear, logistic and Cox regression models.
resultsA total of 83% of patients achieved sCRR for ≥12 months, 56.3% for ≥5 years and 20.4% for ≥10 years. Persistent hydroxychloroquine use (adjusted HR: 1.86, P = 0.004), non-nephrotic baseline proteinuria (adjusted HR: 1.71, P = 0.016) and class III vs class IV LN (HR: 1.89, P = 0.018) were associated with earlier sCRR achievement. The 5- and 10-year post-sCRR risks for renal flares decreased for every additional year on CRR. sCRR duration rather than its mere achievement reduced the risk of ≥30% eGFR decline (adjusted OR: 0.81/year, P = 0.015) and composite ESKD/death (adjusted HR: 0.75/year, P = 0.001). sCRR ≥ 12 months protected against damage accrual (adjusted β-coef=-1.17, P < 0.001). Among those with ≥100-month follow-up, sCRR ≥ 4 years protected against severe kidney function decline (adjusted OR: 0.10, P = 0.005), ESKD/death (adjusted HR: 0.11, P = 0.043) and damage accrual (adjusted β-coef=-0.81, P = 0.012).
conclusionPersistent hydroxychloroquine, non-nephrotic baseline proteinuria and class III vs IV are associated with earlier sCRR. sCRR ≥4 years protects against ≥30% eGFR decline, composite ESKD/death and damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.